SecBot SecBot
PRESS-RELEASE ·Filed Apr 8, 2026

NRIX

Nurix Therapeutics, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss and declining revenue reflect near-term headwinds from lumpy collaboration income, but the pipeline advancement in bexobrutideg remains key. Monitor upcoming Phase 2 enrollment data and IND filing for the tablet formulation as catalysts for sentiment reversal.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$15.60
T+0 close · Apr 8, 2026 · via day close
Latest settled
+53.65%
T+60 · $23.97
Vs SPY
+43.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 8 $15.60entry
  2. T+1 · 7mo ago +4.10%α +3.53% · $16.24
  3. T+5 · 7mo ago +8.78%α +5.27% · $16.97
  4. T+20 · 7mo ago +6.41%α −2.13% · $16.60
  5. T+60 · 4mo ago +53.65%α +43.20% · $23.97
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nurix Therapeutics (NRIX) reported Q1 2026 financial results with revenue of $6.3M, down 66% YoY, and a net loss of $87.2M ($0.79 per share), missing EPS consensus of $-0.73. The miss was driven by lower collaboration revenue as the Sanofi research term wound down, while R&D spending increased to advance bexobrutideg into pivotal trials.

Key Financial Metrics

EPS
−$0.79
est −$0.73 · -8.2%
Revenue
$6.3M
est $15.8M · -60.1% · -66.0% YoY
Rating
strong miss

Key Facts

  • Q1 2026 revenue was $6.3M, down from $18.5M in Q1 2025, primarily due to reduced Sanofi collaboration revenue
  • EPS of $-0.79 missed consensus of $-0.73 by 7.7%, reflecting higher R&D spend
  • R&D expenses rose to $84.1M from $69.7M YoY due to clinical and manufacturing costs for bexobrutideg
  • Cash balance was $540.7M as of February 28, 2026, with no near-term liquidity concerns
  • Company advancing bexobrutideg in pivotal Phase 2 and planned Phase 3 trials for CLL, with tablet formulation IND targeted in 2026

Financial Impact

Revenue down 66% YoY, EPS miss of 7.7% vs consensus, driven by lower collaboration income and higher R&D spend

revenueepsr&d expensesnet loss

Risk Factors

  • Dependence on lumpy collaboration revenue creates volatility in financial results
  • High R&D spend increases cash burn, though current cash runway appears sufficient
  • Clinical trial delays or safety issues in bexobrutideg could negatively impact valuation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3269913

Track record

33 reports on NRIX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  6. Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  7. Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
  8. Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
  9. Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
Showing 10 of 33

US Market Status

Market Closed · Opens Wed (10h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026